KR100774827B1 - 뇌허혈증의 치료방법 및 뇌허혈증의 치료를 위한에리스로포이에틴 또는 에리스로포이에틴 유도체의 용도 - Google Patents

뇌허혈증의 치료방법 및 뇌허혈증의 치료를 위한에리스로포이에틴 또는 에리스로포이에틴 유도체의 용도 Download PDF

Info

Publication number
KR100774827B1
KR100774827B1 KR1020017007421A KR20017007421A KR100774827B1 KR 100774827 B1 KR100774827 B1 KR 100774827B1 KR 1020017007421 A KR1020017007421 A KR 1020017007421A KR 20017007421 A KR20017007421 A KR 20017007421A KR 100774827 B1 KR100774827 B1 KR 100774827B1
Authority
KR
South Korea
Prior art keywords
erythropoietin
cerebral ischemia
treatment
delete delete
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017007421A
Other languages
English (en)
Korean (ko)
Other versions
KR20010082346A (ko
Inventor
한넬로레 에렌라이히
크리스토프 글라이터
Original Assignee
한넬로레 에렌라이히
크리스토프 글라이터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100774827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 한넬로레 에렌라이히, 크리스토프 글라이터 filed Critical 한넬로레 에렌라이히
Publication of KR20010082346A publication Critical patent/KR20010082346A/ko
Application granted granted Critical
Publication of KR100774827B1 publication Critical patent/KR100774827B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
KR1020017007421A 1998-12-14 1999-12-13 뇌허혈증의 치료방법 및 뇌허혈증의 치료를 위한에리스로포이에틴 또는 에리스로포이에틴 유도체의 용도 Expired - Fee Related KR100774827B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
DE19857609.9 1998-12-14

Publications (2)

Publication Number Publication Date
KR20010082346A KR20010082346A (ko) 2001-08-29
KR100774827B1 true KR100774827B1 (ko) 2007-11-07

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017007421A Expired - Fee Related KR100774827B1 (ko) 1998-12-14 1999-12-13 뇌허혈증의 치료방법 및 뇌허혈증의 치료를 위한에리스로포이에틴 또는 에리스로포이에틴 유도체의 용도

Country Status (26)

Country Link
US (1) US7514072B1 (enExample)
EP (1) EP1140139B2 (enExample)
JP (2) JP4750947B2 (enExample)
KR (1) KR100774827B1 (enExample)
CN (1) CN1187085C (enExample)
AT (1) ATE253932T1 (enExample)
AU (1) AU766216C (enExample)
BG (1) BG65417B1 (enExample)
BR (1) BR9916197A (enExample)
CA (1) CA2353553C (enExample)
DE (2) DE19857609A1 (enExample)
DK (1) DK1140139T4 (enExample)
ES (1) ES2211218T5 (enExample)
HK (1) HK1042655B (enExample)
HU (1) HUP0104709A3 (enExample)
ID (1) ID29107A (enExample)
IL (2) IL143579A0 (enExample)
MX (1) MXPA01005971A (enExample)
NO (1) NO330079B1 (enExample)
NZ (1) NZ541591A (enExample)
PL (1) PL202483B1 (enExample)
PT (1) PT1140139E (enExample)
RO (1) RO121409B1 (enExample)
RU (1) RU2242991C2 (enExample)
WO (1) WO2000035475A2 (enExample)
ZA (1) ZA200104626B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US7048934B2 (en) 2001-08-30 2006-05-23 Stem Cell Therapeutics Inc. Combined regulation of neural cell production
ES2383169T3 (es) * 2001-09-14 2012-06-18 Stem Cell Therapeutics Inc. Aumento del número de células madre neurales inducido por prolactina y uso terapéutico del mismo
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
AU2003273615B2 (en) * 2002-06-11 2010-07-29 Brigham And Women's Hospital Neuroprotective synergy of erythropoietin and insulin-like growth factor
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
EP1633383A4 (en) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv USE OF ERYTHROPOIETIN FOR RE-ESTABLISHMENT FOLLOWING A CEREBRAL ISCHEMIC ACCIDENT
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
AU2004277954A1 (en) 2003-09-29 2005-04-14 The Kenneth S Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
PL1675573T4 (pl) * 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
WO2005077404A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
AU2006297041A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
US8333974B2 (en) * 2006-03-17 2012-12-18 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
WO2007142288A1 (ja) * 2006-06-07 2007-12-13 The University Of Tokushima エリスロポエチンを用いた虚血性疾患の治療
NO2170279T3 (enExample) 2007-07-31 2018-05-26
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
WO2012148200A2 (ko) 2011-04-26 2012-11-01 아주대학교 산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05246885A (ja) * 1991-12-26 1993-09-24 Chugai Pharmaceut Co Ltd 脳機能障害による疾患の予防・治療薬

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
ES2127458T3 (es) 1989-11-06 1999-04-16 Cell Genesys Inc Produccion de proteinas utilizando recombinacion homologa.
RU2128227C1 (ru) 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
FI955128L (fi) 1993-04-29 1995-10-27 Abbott Lab Erytropoietiinianalogikoostumuksia ja menetelmä niiden valmistamiseksi ja käyttämiseksi
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
TR200103785T2 (tr) 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05246885A (ja) * 1991-12-26 1993-09-24 Chugai Pharmaceut Co Ltd 脳機能障害による疾患の予防・治療薬

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Acta Neuropathol. Vol.94, pp.158-163 (1997) *
Acta Neuropathol., 94, 158-163.
JP 평5-246885.
PNAS 95, 4635-4640.
Proc. Natl. Acad. Sci. USA, Vol.95, pp.4635-4640 (1998. 4.) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Also Published As

Publication number Publication date
AU766216C (en) 2004-11-11
BG105575A (en) 2002-01-31
IL143579A0 (en) 2002-04-21
DK1140139T4 (da) 2009-06-08
NZ541591A (en) 2007-08-31
JP2011079860A (ja) 2011-04-21
PT1140139E (pt) 2004-04-30
KR20010082346A (ko) 2001-08-29
EP1140139B1 (de) 2003-11-12
WO2000035475A2 (de) 2000-06-22
RO121409B1 (ro) 2007-05-30
BR9916197A (pt) 2001-09-04
DE59907752D1 (de) 2003-12-18
CA2353553A1 (en) 2000-06-22
ZA200104626B (en) 2002-09-06
HK1042655A1 (en) 2002-08-23
JP4750947B2 (ja) 2011-08-17
NO20012896L (no) 2001-08-14
NO330079B1 (no) 2011-02-14
AU2283100A (en) 2000-07-03
EP1140139B2 (de) 2009-03-18
IL143579A (en) 2007-10-31
PL349335A1 (en) 2002-07-15
ATE253932T1 (de) 2003-11-15
ES2211218T5 (es) 2009-06-03
JP2002532432A (ja) 2002-10-02
EP1140139A2 (de) 2001-10-10
AU766216B2 (en) 2003-10-09
NO20012896D0 (no) 2001-06-12
CN1335776A (zh) 2002-02-13
PL202483B1 (pl) 2009-06-30
MXPA01005971A (es) 2002-03-27
RU2242991C2 (ru) 2004-12-27
ID29107A (id) 2001-07-26
DE19857609A1 (de) 2000-06-15
HUP0104709A3 (en) 2002-05-28
HUP0104709A2 (hu) 2002-04-29
EP1140139B9 (de) 2004-03-31
DK1140139T3 (da) 2004-03-15
BG65417B1 (bg) 2008-07-31
US7514072B1 (en) 2009-04-07
HK1042655B (zh) 2005-09-23
WO2000035475A3 (de) 2000-10-19
ES2211218T3 (es) 2004-07-01
CN1187085C (zh) 2005-02-02
CA2353553C (en) 2011-05-17

Similar Documents

Publication Publication Date Title
KR100774827B1 (ko) 뇌허혈증의 치료방법 및 뇌허혈증의 치료를 위한에리스로포이에틴 또는 에리스로포이에틴 유도체의 용도
Pelleymounter et al. Characteristics of BDNF-induced weight loss
US20040209812A1 (en) Use of erythropoietin in stroke recovery
JPH03190823A (ja) エリスロポエチン皮下又は筋肉投与剤
US20060166885A1 (en) Treatment and prevention of decubitus
CA2226580A1 (en) Method of treating epilepsy with brain derived neurotrophic factor
Toleubayev et al. Regenerative properties of recombinant human erythropoietin in the Wound Healing
CN109865127B (zh) 经修饰的胸腺素β4在治疗糖尿病周围神经病变方面的用途
US20250082725A1 (en) Methods for preventing and treating brain inflammation
US20030083250A1 (en) Anti-tumor chemotherapy by administration of cyclophosphamide and erythropoeitin
ZA200508695B (en) Use of erythropoietin in stroke recovery

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20070921

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2001 7007421

Appeal request date: 20070117

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2007101000552

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080415

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007748270000

Gazette reference publication date: 20071107

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20131028

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20141023

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151102

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151102